C. Kizilarslanoglu Et Al. , "Nine-weeks of adjuvant trastuzumab in HER2-positive breast cancer: A single center experience," 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , vol.30, Illinois, United States Of America, 2012
Kizilarslanoglu, C. Et Al. 2012. Nine-weeks of adjuvant trastuzumab in HER2-positive breast cancer: A single center experience. 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , (Illinois, United States Of America).
Kizilarslanoglu, C., Petekkaya, I., Babacan, T., & Altundag, K., (2012). Nine-weeks of adjuvant trastuzumab in HER2-positive breast cancer: A single center experience . 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America
Kizilarslanoglu, Cemal Et Al. "Nine-weeks of adjuvant trastuzumab in HER2-positive breast cancer: A single center experience," 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2012
Kizilarslanoglu, Cemal Et Al. "Nine-weeks of adjuvant trastuzumab in HER2-positive breast cancer: A single center experience." 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America, 2012
Kizilarslanoglu, C. Et Al. (2012) . "Nine-weeks of adjuvant trastuzumab in HER2-positive breast cancer: A single center experience." 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America.
@conferencepaper{conferencepaper, author={Cemal Kizilarslanoglu Et Al. }, title={Nine-weeks of adjuvant trastuzumab in HER2-positive breast cancer: A single center experience}, congress name={48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)}, city={Illinois}, country={United States Of America}, year={2012}}